Posts filtered by tags: Bancel[x]


 

EU's Covid vaccination debacle is down to institutional inflexibility

Supply delays underline there was no legal or economic justification for central planningA storm is raging over the EU’s failure to have ordered more of the approved Covid-19 vaccines ahead of time. Stéphane Bancel, the chief executive of the US pharmaceutical company Moderna, which gained approval for its vaccine shortly after Pfizer/BioNTech, claims that the EU has relied too much on “vaccines from its own laboratories”.Did the European commission prioritise supporting its own pharmaceutical i...
Tags: Europe, Business, China, US, Eu, European Union, UK News, World news, US news, European Commission, Astrazeneca, Pharmaceuticals industry, Vaccines and immunisation, Pfizer, Moderna, Fosun Pharma


Moderna CEO says data on the Covid-19 vaccine in young children likely won't be available until 2022

A nurse prepares a coronavirus vaccine shot developed by the National Institutes of Health and Moderna Inc., July 2020. Hans Pennink/AP Hans Pennink/AP Data on Moderna's Covid-19 vaccine in young children won't be available until 2022, CEO says at JPMorgan Healthcare conference. The study will take longer because they have to start at a much lower dose. Studies have already begun in children ages 12 and up. Visit Business Insider's homepage for more stories. Moderna will begin studying the...
Tags: News, Trends, Healthcare, Food And Drug Administration, Pfizer, Vaccine, Disneyland Resort, Centers For Disease Control And Prevention, Jpmorgan, Moderna, JPMorgan Healthcare, Stéphane Bancel, Hans Pennink, Coronavirus, Bancel, COVID-19


What to say to a friend who's skeptical of getting the coronavirus vaccine

Ohio State employee Lauren Chisholm, left, receives a Pfizer-BioNTech COVID-19 vaccination from Robert Weber AP Photo/Jay LaPrete The FDA has authorized two coronavirus vaccines for emergency use. Neither vaccine raised any major safety concerns in large clinical trials among diverse groups of volunteers. Here are nine reasons to be confident in the safety of these vaccines. Visit Business Insider's homepage for more stories. Around 5.3 million initial doses of the coronavirus vaccine have...
Tags: Hong Kong, Science, News, Cdc, Senate, US, Toronto, Trends, Features, Atlantic, Washington Dc, New York Times, National Institutes of Health, Columbia University, Philadelphia, Fda


The US just authorized Moderna's coronavirus vaccine, making millions more doses available to help curb the pandemic

Moderna; Samantha Lee/Business Insider US regulators have authorized a second coronavirus vaccine for emergency use.  This two-dose vaccine, developed by the biotech firm Moderna and the US National Institutes of Health, was about 94% effective at preventing COVID-19 in a large clinical trial. Moderna's vaccine is easier to store and transport than Pfizer's COVID-19 shot, which got US clearance a week ago. Moderna plans to deliver 20 million doses in the US by year's end.  The authorizati...
Tags: Health, Science, News, China, Massachusetts, Russia, US, Trends, United States, Healthcare, Astrazeneca, Fda, Pfizer, University of Oxford, Anthony Fauci, Low


9 things to say to a friend who's skeptical of getting the coronavirus vaccine

Ohio State employee Lauren Chisholm, left, receives a Pfizer-BioNTech COVID-19 vaccination from Robert Weber AP Photo/Jay LaPrete The FDA authorized the coronavirus vaccine from Pfizer and BioNTech for emergency use on Friday. Moderna's coronavirus vaccine is likely to be next. Neither vaccine raised any major safety concerns in large clinical trials among diverse groups of volunteers. Here are nine reasons to be confident in the safety of these vaccines. Visit Business Insider's homepage ...
Tags: Hong Kong, Science, News, Cdc, Senate, US, Toronto, Trends, Features, Atlantic, Washington Dc, New York Times, Food And Drug Administration, Columbia University, Philadelphia, Fda


The FDA will likely grant Moderna's COVID-19 vaccine emergency use authorization on Friday

A nurse prepares a coronavirus vaccine shot developed by the National Institutes of Health and Moderna Inc., July 2020. Hans Pennink/AP The US Food and Drug Administration will approve the Moderna vaccine on Friday, The New York Times reported. FDA regulators confirmed Moderna's vaccine was 94.1% effective at preventing COVID-19 in late-stage trials, per agency documents released Tuesday. The US bought 200 million doses of Moderna's vaccine as of December 15. Moderna CEO Stéphane Bancel pr...
Tags: Politics, Science, News, White House, US, Trends, New York Times, Healthcare, Oxford, Astrazeneca, Fda, Pfizer, Vaccine, Oxford University, Times, Johnson Johnson


Moderna just asked the FDA to authorize its coronavirus vaccine, a key step before it can be given to more people

Moderna CEO Stéphane Bancel at a meeting with President Donald Trump, members of the White House coronavirus task force, and pharmaceutical executives on March 2. Andrew Harnik/AP Images Moderna filed for emergency-use authorization of its experimental coronavirus vaccine, the company announced on Monday. The biotech company said its vaccine was 94.1% effective against COVID-19 in an analysis of a late-stage trial. If the Food and Drug Administration authorizes the vaccine, the US intends ...
Tags: White House, US, Trends, New York Times, Food And Drug Administration, Astrazeneca, Fda, Pfizer, University of Oxford, Donald Trump, Anthony Fauci, Health And Human Services, US Food and Drug Administration, Fauci, Marks, Moderna


Moderna CEO said he hopes to be vaccinating Americans 'within 24 hours' of an FDA green light

Moderna CEO Stephane Bancel attends a meeting with President Donald Trump, members of the Coronavirus Task Force, and pharmaceutical executives in the Cabinet Room of the White House on March 2, 2020. Andrew Harnik/AP Images Moderna announced it will file for emergency use-authorization with the US Food and Drug Administration on Monday. CEO Stéphane Bancel said the company aims to start vaccinating Americans within "24 hours after the FDA gives an approval." Moderna said the vaccine was 9...
Tags: News, White House, US, Trends, Healthcare, Astrazeneca, Fda, Pfizer, University of Oxford, Donald Trump, Fox Business, Johnson Johnson, US Food and Drug Administration, Department of Health and Human Services, Andrew Harnik, Moderna


Moderna is set to ask the FDA to authorize its coronavirus vaccine, a key step before it can be given to more people

Moderna CEO Stephane Bancel attends a meeting with President Donald Trump, members of the Coronavirus Task Force, and pharmaceutical executives in the Cabinet Room of the White House on March 2, 2020. Andrew Harnik/AP Images Moderna will file today for emergency use authorization of its experimental coronavirus vaccine. The biotech company said the vaccine was 94.1% effective against COVID-19 in an analysis of a late-stage trial. If the FDA authorizes the vaccine, the US intends to start v...
Tags: White House, US, Trends, New York Times, Oxford, Astrazeneca, Fda, Pfizer, Donald Trump, Anthony Fauci, Health And Human Services, Fauci, Marks, Andrew Harnik, Moderna, Azar


Moderna's groundbreaking coronavirus vaccine was designed in just 2 days

Moderna; Samantha Lee/Business Insider Moderna's coronavirus vaccine candidate is 94.5% effective at protecting people against COVID-19, according to the company. The candidate took under a year to develop and test, which is years faster than previous vaccines. The company designed its vaccine candidate in just two days. In contrast, traditional vaccines can take years to design. Visit Business Insider's homepage for more stories. Moderna's coronavirus vaccine candidate was found to be 94...
Tags: China, Trends, Atlantic, New York Times, Astrazeneca, Graham, Fda, Pfizer, Anthony Fauci, Nih, American Lung Association, Rizzo, The Food and Drug Administration, Seattle Washington, Novavax, Wuhan China


Moderna's CEO sold nearly $2 million of his stock ahead of the company's emergency use vaccine filing. He's now worth $3 billion.

Moderna CEO, Stephane Bancel. Andrew Dunn/Business Insider Moderna CEO Stephane Bancel sold almost $2 million in shares ahead of the company's emergency use authorization filing for its COVID-19 vaccine.Bancel sold a total of 19,000 shares between November 18-19 as part of a predetermined trading plan amended May 21, according to a filing with the SEC.Moderna is the second major drug company to announce success in a late-stage COVID-19 vaccine trial. It expects to file for FDA approval by t...
Tags: Trends, Markets, Billionaires, SEC, Stocks, Fda, Pfizer, Goldman, Pharmaceutical, Pharma Company, Moderna, Healthcare Stocks, Stéphane Bancel, Albert Bourla, Coronavirus, Bancel


SoulCycle's top instructors had sex with clients, 'fat-shamed' coworkers, and used homophobic and racist language, insiders say

Hello everyone! Welcome to this weekly roundup of Business Insider stories from co-Editor in Chief Matt Turner. Subscribe here to get this newsletter in your inbox every Sunday.Read on for more on SoulCycle's top instructors mistreating staff, Moderna's research revolution, and Google CEO Sundar Pichai's leadership shift. Bryan R. Smith/Getty; BFA; Olivia Atherton; Skye Gould/Business Insider Hello!We now have two promising coronavirus vaccines, with Moderna's promising results this week...
Tags: Google, Amazon, Hollywood, California, France, China, Trends, Nike, Palo Alto, Larry Page, Atlantic, Sergey Brin, Retail, Silicon Valley, Graham, Pfizer


Moderna's CEO says vaccines aren't a 'silver bullet,' people must still social distance and wear masks

Moderna CEO Stephane Bancel attends a meeting with President Donald Trump. Andrew Harnik/AP Images Wearing a mask and social distancing are the "best weapon" to control the virus, according to Moderna CEO Stéphane Bancel. Bancel spoke at the Bloomberg New Economy Forum on Thursday.  Moderna recently announced that its experimental vaccine was 94.5% effective against the new coronavirus. Bancel said in a recent interview with Business Insider that the public will have access to a vaccine by...
Tags: News, US, Trends, Bloomberg, Healthcare, Fda, Anthony Fauci, Chinese Center for Disease Control and Prevention, Moderna, Stéphane Bancel, Bloomberg New Economy Forum, Allana Akhtar, Coronavirus, Bancel, Coronavirus Vaccine, Covid-19 Vaccine


Meet Stéphane Bancel, the CEO of Moderna, a company developing a coronavirus vaccine in record time that is showing early signs of success in a preliminary study

Moderna CEO Stephane Bancel attends 2019 Forbes Healthcare Summit at the Jazz at Lincoln Center on Dec. 5, 2019 in New York City. Steven Ferdman/Getty Images Stéphane Bancel is the CEO of Moderna, the company that translated the genetic code of the coronavirus into a vaccine. Moderna released results on Monday that said its vaccine is 94.5% effective in preventing COVID-19; human trials began in March. It typically takes several years to develop a vaccine.  The vaccine uses messenger RNA, ...
Tags: France, White House, Massachusetts, New York City, US, Trends, Strategy, Features, Healthcare, Fda, Pfizer, Vaccine, Lincoln Center, Biotech, Donald Trump, Biotechnology


7 unanswered questions about the coronavirus vaccines from Pfizer and Moderna

Xinhua/Gil Cohen Magen via Getty Images There are now two vaccine trials with promising results, but there are plenty of caveats to the good news. We still don't know whether the vaccine protects against asymptomatic cases or if it even lowers the risk of spreading COVID-19. The two companies behind the vaccines, Pfizer and Moderna, have yet to publish their vaccine data in medical journals, and both are pending approval by the FDA. Visit Business Insider's homepage for more stories. Two ...
Tags: Trends, Salmon, Poland, World Health Organization, Astrazeneca, Fda, Pfizer, Anthony Fauci, Wall Street Journal, Mayo Clinic, Johnson Johnson, Fauci, US Health and Human Services, Moderna, National Academies of Sciences, Stéphane Bancel


Moderna's coronavirus vaccine is effective at preventing COVID-19, joining Pfizer's shot. Here's what you need to know.

Nurse Practitioner Gabriela Huyke prepares for medical examination of a volunteer for a coronavirus vaccine study. Chandan Khanna/AFP via Getty Moderna said its experimental coronavirus vaccine helps prevent COVID-19. The news comes just a week after Pfizer shared that its coronavirus vaccine is also effective. It's a big victory in the fight against the pandemic, but the data hasn't been published in a peer-reviewed journal, and regulators haven't reviewed the vaccine. Here's what having ...
Tags: Health, Science, US, Trends, Healthcare, Food And Drug Administration, Fda, Pfizer, Vaccine, Seattle, Anthony Fauci, Zika, Paul Offit, Center for Biologics Evaluation and Research, Pandemic, Moderna


The CEO of Moderna says every American will likely have access to a COVID-19 vaccine by June 2021

Moderna CEO Stephane Bancel. Andrew Harnik/AP Images Moderna CEO Stephane Bancel told Business Insider that a coronavirus vaccine will available to any American adult who wants one by June.  The upstart Massachusetts biotech company said Monday that its experimental vaccine was highly effective at preventing COVID-19 in a late-stage study. Bancel shared his prediction for how the next year plays out as vaccines are distributed, including a return to normal in summer 2021 for the US. For mo...
Tags: Health, Science, Massachusetts, US, Trends, Healthcare, Fda, Pfizer, Biotech, Anthony Fauci, Business Insider, Health And Human Services, US Food and Drug Administration, Fauci, EUA, Moderna


Moderna says its coronavirus vaccine is 94.5% effective against COVID-19, a crucial victory in the fight against the pandemic

Moderna Therapeutics seen during COVID-19 in Massachusetts Reuters Moderna's experimental coronavirus vaccine was highly effective at preventing COVID-19, the Massachusetts biotech company said on Monday. The finding comes from a 30,000-person study that compared volunteers who got a two-dose regimen of Moderna's shot to ones who got a placebo. The vaccine was shown to be 94.5% effective in a preliminary analysis. The announcement closely follows similar news from a rival vaccine program b...
Tags: Health, Science, News, Ipo, Massachusetts, US, Trends, Healthcare, Fda, Pfizer, Biotech, Zika, Johnson Johnson, US Food and Drug Administration, Sanofi, Cambridge Massachusetts


Moderna just finished recruiting 30,000 people for its coronavirus vaccine trial. One graph reveals how the biotech slowed down its research to recruit more minorities.

A volunteer receives an injection from a medical worker during the country's first human clinical trial for a potential vaccine against the novel coronavirus, at Baragwanath Hospital in Soweto, South Africa, June 24, 2020. REUTERS/Siphiwe Sibeko The coronavirus vaccine frontrunner Moderna has finished enrolling volunteers for its final clinical trial, the biotech said Thursday.  The 30,000-person study is expected to produce data showing whether or not the vaccine prevents symptomatic ...
Tags: Health, Science, Massachusetts, US, Trends, Healthcare, Pfizer, Business Insider, Soweto South Africa, Moderna, Siphiwe Sibeko, Andrew Dunn, Stéphane Bancel, Coronavirus, Bancel, Coronavirus Vaccine


Moderna says COVID-19 vaccine could be approved in December

Stéphane Bancel, chief executive of Moderna Inc., said Monday that the federal government could grant emergency use authorization for its COVID-19 vaccine in December, assuming the company gets promising data from its Phase 3 trial in November. Moderna started its final-phase trial with 30,000 volunteers in July, and in order to apply for emergency authorization, 53 of the subjects have to become infected with the new coronavirus, and the cases have to be significantly higher in the half of the ...
Tags: News, Astrazeneca, Pfizer, Wall Street Journal, Johnson Johnson, Roe, Moderna, Stéphane Bancel, Moderna Inc, Bancel, Will Kansas, Under Food and Drug Administration


Moderna CEO expects COVID-19 vaccine interim results in November: WSJ

Speaking at the newspaper's annual Tech Live conference, Bancel also said sufficient interim results from the study takes longer to get and that the government's permission to use the vaccine may not come until next year. The first interim analysis of the vaccine's efficacy will happen when 53 people in the entire study get symptomatic COVID-19, the report said. "That first analysis is likely to occur in November, but it's hard to predict exactly which week because it depends on the cases, the...
Tags: News, Bancel, COVID


Moderna CEO says the global population could start getting access to its vaccine by late March or early April 2021

Moderna CEO Stephane Bancel at the 2019 Forbes Healthcare Summit in New York City in December 2019. Steven Ferdman/Getty Images The CEO of Moderna said Wednesday that he expects its coronavirus vaccine to be ready for use in late March or early April 2021. "I think a late Q1, early Q2 approval is a reasonable timeline," Stéphane Bancel told a conference hosted by the Financial Times. Bancel added that Moderna would be ready to submit the vaccine to the US Food and Drug Administration for "...
Tags: Politics, New York City, US, Trends, Healthcare, News UK, Fda, Associated Press, Pfizer, Vaccine, Donald Trump, Cnbc, Trump, US Food and Drug Administration, US Food and Drug Administration FDA, EUA


5 takeaways from the US coronavirus vaccine plan

Welcome to Business Insider's daily healthcare newsletter, your daily dose of pharma, biotech, and healthcare news. Subscribe here to get this newsletter in your inbox every weekday. Hollis Johnson/Business Insider Hello,Today in healthcare news: American Well is set to make its public-market debut after raising $742 million by pricing at $18 a share on Wednesday night. Elsewhere: What you need to know about the plan to get Americans vaccinated, when the director of the CDC expects every...
Tags: Cdc, Senate, White House, US, Trends, Bloomberg, House, Donald Trump, Illumina, Trump, Harpersville, Lilly, Binghamton, Department of Health and Human Services, Centers for Disease Control and Prevention CDC, Redfield


Moderna's CEO told us we should know if the biotech's coronavirus vaccine works in November

Moderna CEO Stephane Bancel attends a meeting with President Donald Trump, members of the Coronavirus Task Force, and pharmaceutical executives in the Cabinet Room of the White House on March 2, 2020. Andrew Harnik/AP Images Moderna CEO Stephane Bancel said it's likely we'll know if Moderna's experimental coronavirus vaccine works in November.  The timing depends in part on how effective the shot actually is at preventing disease. The more effective the vaccine is, the quicker a board of i...
Tags: Health, UK, New York, Science, White House, Massachusetts, US, Trends, Healthcare, Astrazeneca, Pfizer, Donald Trump, Moderna, Cabinet Room, Andrew Dunn, Stéphane Bancel


$29 billion biotech company Moderna just signed a big cloud deal with Amazon Web Services, even as the race for a COVID-19 vaccine accelerates

Biotech company Moderna on Wednesday announced that it has chosen Amazon Web Services as its preferred cloud partner. The company is seen as a leader in COVID-19 vaccine research, entering its third phase of clinical trials late July. Visit Business Insider's homepage for more stories. $29 billion biotech company Moderna announced a new partnership with Amazon Web Services on Wednesday that will see the cloud giant become its "preferred" cloud provider. The deal will also see Moderna tap AWS ...
Tags: Microsoft, Trends, United States, Aws, Novartis, Amazon Web Services, Moderna, Michael Yee, Bancel, COVID


We just got some promising early data on Moderna's coronavirus vaccine. Here's the inside story of how the biotech upstart developed the shot in record time.

The biotech Moderna developed a potential coronavirus vaccine in record time, zooming past Big Pharma competitors. Stephane Bancel, the company's CEO, sat down with Business Insider to discuss the technology platform that drove its speed and how the company hopes to pioneer a new way of developing vaccines.  "The speed is one dimension, but the piece that excites me the most about this technology is we can do vaccines that cannot be done using traditional technology," Bancel said in an intervi...
Tags: France, China, Trends, Nih, Wall Street Journal, Big Pharma, Moderna, Lydia Ramsey, Vaccine Research Center, Stéphane Bancel, Bancel, Massachusetts Stephane Bancel, Barney Graham, National Institutes of Health Graham


The untold story of Moderna as the biotech's coronavirus vaccine faces a test that could make it one of the most consequential startups of all time (MRNA)

The biotech Moderna has skyrocketed to global prominence, leading the world's race for a coronavirus vaccine. The Cambridge, Massachusetts-based biotech was founded in 2010 with the ambitious goal to develop a new type of medicine. While its platform remains unproven, it is now being tested under the brightest possible spotlight of a pandemic.  Here's the inside story of Moderna's rise, from an offshoot of stem cell research to routinely shattering funding records on its way to biotech's top r...
Tags: Google, Amazon, Microsoft, Navy, California, Washington Post, France, China, US, Trends, Merck, Mit, Harvard, Cambridge, Astrazeneca, Fidelity


We just got some promising early data on Moderna's coronavirus vaccine. Here's the inside story of how the biotech upstart developed the injection in record time.

The biotech Moderna developed a potential coronavirus vaccine in record time, zooming past Big Pharma competitors. Stephane Bancel, the company's CEO, sat down with Business Insider to discuss the technology platform that drove its speed and how the company hopes to pioneer a new way of developing vaccines.  "The speed is one dimension, but the piece that excites me the most about this technology is we can do vaccines that cannot be done using traditional technology," Bancel said in an intervi...
Tags: Navy, France, China, US, Trends, Nih, Wall Street Journal, Big Pharma, Moderna, Lydia Ramsey, Vaccine Research Center, Stéphane Bancel, Bancel, Massachusetts Stephane Bancel, Barney Graham, National Institutes of Health Graham


Moderna just sped up the timeline for testing its promising coronavirus vaccine. We got the inside story on how the biotech upstart developed the injection in record time.

The biotech Moderna developed a potential coronavirus vaccine in record time, zooming past Big Pharma competitors. Stephane Bancel, the company's CEO, sat down with Business Insider to discuss the technology platform that drove its speed and how the company hopes to pioneer a new way of developing vaccines.  "The speed is one dimension, but the piece that excites me the most about this technology is we can do vaccines that cannot be done using traditional technology," Bancel said in an intervi...
Tags: Navy, France, China, US, Trends, Nih, Wall Street Journal, Big Pharma, Moderna, Vaccine Research Center, Stéphane Bancel, Bancel, Massachusetts Stephane Bancel, Barney Graham, National Institutes of Health Graham


How coronavirus is upending corporate America

Hello! There's really only one business story in the world right now, and that's coronavirus. Here's what you need to now: How hospitals are preparing  Hospitals are bracing for what could be millions of admissions nationwide as the virus spreads, Lydia Ramsey reports. She writes: The American Hospital Association, which represents thousands of hospitals and health systems, hosted a webinar in February with its member hospitals and health systems. Business Insider obtained a copy of the slide...
Tags: Apple, Google, Facebook, Japan, New York, Microsoft, NYC, US, America, San Francisco, Trends, Cisco, Bank Of America, Rebecca, Switzerland, Ubs